App-Quantinova.ai

Amlexanox As a Possible Breakthrough Drug for MLL/AF4-Positive Acute Lymphoblastic Leukemia

Hayato Tamai - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Amlexanox

Germline Genetic Variations in Methotrexate Candidate Genes Are Associated with Pharmacokinetics and Outcome in Pediatric Acute Lymphoblastic Leukemia in China

Shuguang Liu - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Acute lymphoblastic leukemia

Methotrexate

Outcomes of Childhood Acute Lymphoblastic Leukemia with CNS-2, CNS-3 and Traumatic Lumbar Puncture with Blasts in Two Eras of Taiwan Pediatric Oncology Group (TPOG)-ALL-2002 Study with or without Cranial Radiation

Hsi-Che Liu - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Dissecting the Outcome Difference Between Children and Adolescents and Young Adults (AYAs) with Acute Lymphoblastic Leukemia (ALL)

Julie A. Wolfson - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response

Caner Saygin - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Koji Sasaki - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients

Xun Lai - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

PI3K and MEK Inhibition in Hypodiploid Acute Lymphoblastic Leukemia

Evan Comeaux - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

TP53

Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage

Bhumika Patel - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Somatic and Germline Mutational Heterogeneity in High Hyperdiploid Acute Lymphoblastic Leukemia

Adam J de Smith - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium

Thai Hoa Tran - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Relapse Prediction By Flow Cytometric Minimal Residual Disease Assessment in Infants with Acute Lymphoblastic Leukemia

Alexander Popov - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Landscape of Somatic Mutations and Gene Expression Changes in Relapsed Infant MLL-Rearranged Acute Lymphoblastic Leukemia

Rumen Kostadinov - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Mir Expression Profile of Peripheral Blood Lymphocytes Predicts Relapse in Pediatric Acute Lymphoblastic Leukemia

Smadar Avigad - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Mofezolac

Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality

Nicholas J. Short - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosomea-Positive Chronic Myeloid Leukemia

Vamsi Kota - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Bosutinib

Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide Using As Conditioning Fludarabine Melphalan Plus 200-400cGy of Total Body Irradiation. Very Good Balance Between Tolerance and Anti Leukemic Activity

Amado J Karduss-Urueta - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Matched Sibling Versus Haploidentical Hematopoietic Transplant for Adult Patients with Acute Lymphoblastic Leukemia

Yi Luo - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Filgrastim

Sociodemographic Disparities in Chemotherapy and Hematopoietic Cell Transplantation Utilization Among Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Patients

Matthew J. Wieduwilt - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Adolescent and Young Adult Oncology Patients with Acute Lymphoblastic Leukemia: Shifting Location of Care over Time

Elysia Alvarez - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Filters

2187 Abstracts